期刊文献+

英夫利昔与依那西普治疗幼年特发性关节炎的效果对比 被引量:1

下载PDF
导出
摘要 目的:分析和比较用英夫利昔与依那西普治疗幼年特发性关节炎的效果。方法:对近年来安徽省儿童医院收治的30例幼年特发性关节炎患儿的临床资料进行回顾性研究。将这30例患儿随机分为甲组和乙组。对两组患儿均进行常规治疗。在此基础上,加用英夫利昔对甲组患儿进行治疗,加用依那西普对乙组患儿进行治疗,然后比较两组患儿的各项临床指标。结果:治疗3个月、6个月和12个月后,两组患儿的DAS28评分、ESR和CRP的水平较治疗前均明显下降(P<0.05),但组间相比差异无统计学意义(P>0.05)。治疗3个月后,乙组患儿治疗的总有效率高于甲组患儿(P<0.05)。治疗12个月后,甲组患儿治疗的总有效率高于乙组患儿(P<0.05)。结论:在对幼年特发性关节炎患儿进行常规治疗的同时,加用英夫利昔与依那西普进行治疗均能收到良好的效果。但依那西普的起效较快,而英夫利昔的远期疗效较好,临床上应根据患儿的实际情况为其合理用药。
作者 何孝亮
机构地区 安徽省儿童医院
出处 《当代医药论丛》 2018年第9期96-97,共2页
  • 相关文献

参考文献4

二级参考文献33

  • 1唐雪梅,李秋,徐培菊,王丽佳,王墨.幼年类风湿性关节炎临床特征分析及治疗效果比较[J].儿科药学杂志,2004,10(3):28-29. 被引量:5
  • 2汪向东.症状自评量表[J].中国心理卫生杂志,1993,7:31-31.
  • 3Salaffi F, Cimmino MA, Leardini G, et al.Disease activity assess- ment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI) [J].Clin Exp Rheumatol, 2009, 27(4) :552-559.
  • 4Wallace CA, Ruperto N, Giannini EH.Preliminary criteria for clinical remission for select categories of juvenile idiopathic ar- thritis[J ].J Rheumatol, 2004, 31 ( 11 ) : 2290-2294.
  • 5Ravelli A, Martini A.Remission in juvenile idiopathic arthri- tis [J ].Clin Exp Rheumatol, 2006,24 ($43) : 105-110.
  • 6Lloyd S, Bujkiewicz Sa, Wailoo AJ, et al.The effectiveness of an- ti-TNF-a therapies when used sequentially in rheumatoid ar- thritis patients: a systematic review and meta-analysis[J]. Rheumatology, 2010,49 : 2313-2321.
  • 7Nishida K, Okada Y, Nawata M, et al.lnduction of hyperadipo- nectinemia following long-term treatment of patients with rheu-matoid arthritis with infliximab (IFX), an anti-TNF-alpha anti- body[J ].Endocr J, 2008,55( 1 ) :213-216.
  • 8Merete LH, Ib-Jarle C, Ulrik T, et al. Direct comparison of treat- ment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab [J ].Arth Rheum, 2010,62( 1 ) : 22-32.
  • 9Michael EW, Joan MB, Joel MK, et al.Safety and efficacy of etan- ercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis [J].Arthrit Care Res,2011,63(3) :373-382.
  • 10Lamot L, Bukovac LT, Vidovic M, et al.The"head-to-head"com- parison of etanercept and infliximab in treating children with ju- venile idiopathic arthritis [J].Clin Exp Rheumatol, 2011, 29: 131-139.

共引文献21

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部